The DOI matches its Crossref record; 539 of the 539 references it cites were found in a registry or an index.
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Abstract
Since 1984, when paclitaxel was approved by the FDA for the treatment of advanced ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor agents. However, their historic classification as antimitotics does not describe all their functions. Indeed, taxanes act in a complex manner, altering multiple cellular oncogenic processes including mitosis, angiogenesis, apoptosis, inflammatory response, and ROS production. On the one hand, identification of the diverse effects of taxanes on oncogenic signaling pathways provides opportunities to apply these cytotoxic drugs in a more rational manner. On the other hand, this may facilitate the development of novel treatment modalities to surmount anticancer drug resistance. In the latter respect, chemoresistance remains a major impediment which limits the efficacy of antitumor chemotherapy. Taxanes have shown impact on key molecular mechanisms including disruption of mitotic spindle, mitosis slippage and inhibition of angiogenesis. Furthermore, there is an emerging contribution of cellular processes including autophagy, oxidative stress, epigenetic alterations and microRNAs deregulation to the acquisition of taxane resistance. Hence, these two lines of findings are currently promoting a more rational and efficacious taxane application as well as development of novel molecular strategies to enhance the efficacy of taxane-based cancer treatment while overcoming drug resistance. This review provides a general and comprehensive picture on the use of taxanes in cancer treatment. In particular, we describe the history of application of taxanes in anticancer therapeutics, the synthesis of the different drugs belonging to this class of cytotoxic compounds, their features and the differences between them. We further dissect the molecular mechanisms of action of taxanes and the molecular basis underlying the onset of taxane resistance. We further delineate the possible modalities to overcome chemoresistance to taxanes, such as increasing drug solubility, delivery and pharmacokinetics, overcoming microtubule alterations or mitotic slippage, inhibiting drug efflux pumps or drug metabolism, targeting redox metabolism, immune response, and other cellular functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 401–539 of 539
Wang, S., Wang, Z., Boise, L., Dent, P., & Grant, S. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0669 · Cited by 66
Synthesis and structure-activity relationships of new second-generation taxoids
Ojima, I., Wang, T., Miller, M. L., Lin, S., Borella, C. P., Geng, X., Pera, P. J., & Bernacki, R. J. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00629-0 · Cited by 66
Yang, S. X., Costantino, J. P., Kim, C., Mamounas, E. P., Nguyen, D., Jeong, J., Wolmark, N., Kidwell, K., Paik, S., & Swain, S. M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.1602 · Cited by 66
The Elephant in the Room: The Role of Microtubules in Cancer
Cirillo, L., Gotta, M., & Meraldi, P. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-57127-0_5 · Cited by 66
Padar, S., van Breemen, C., Thomas, D. W., et al. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705755 · Cited by 64
Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India
Ranade, A. A., Joshi, D. A., Phadke, G. K., Patil, P. P., Kasbekar, R. B., Apte, T. G., Dasare, R. R., Mengde, S. D., Parikh, P. M., Bhattacharyya, G. S., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt322 · Cited by 64
Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer
Kroon, J., Kooijman, S., Cho, N.-J., Storm, G., & van der Pluijm, G. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.03.003 · Cited by 64
Januchowski, R., Wojtowicz, K., Andrzejewska, M., & Zabel, M. (2013) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2013.09.004 · Cited by 63
Kosaka, T., Miyajima, A., Shirotake, S., Suzuki, E., Kikuchi, E., & Oya, M. (2011) · The Journal of Urology · doi:10.1016/j.juro.2011.02.016 · Cited by 62
Huang, S., Zhang, Y., Wang, L., Liu, W., Xiao, L., Lin, Q., Gong, T., Sun, X., He, Q., Zhang, Z., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.049 · Cited by 62
Stark, M., Silva, T. F. D., Levin, G., Machuqueiro, M., & Assaraf, Y. G. (2020) · Cells · doi:10.3390/cells9051082 · Cited by 62
Self-citationTherapy‐induced enrichment of putative lung cancer stem‐like cells
Freitas, D. P., Teixeira, C. A., Santos‐Silva, F., Vasconcelos, M. H., & Almeida, G. M. (2013) · International Journal of Cancer · doi:10.1002/ijc.28478 · Cited by 61
ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview
Arrigoni, E., Galimberti, S., Petrini, M., Danesi, R., & Paolo, A. D. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1215423 · Cited by 61
Prolonged mitotic arrest induced by Wee1 inhibition sensitizes breast cancer cells to paclitaxel
Lewis, C. W., Jin, Z., Macdonald, D., Wei, W., Qian, X. J., Choi, W. S., He, R., Sun, X., & Chan, G. K. T. (2017) · Oncotarget · doi:10.18632/oncotarget.17848 · Cited by 61
Liu, C., Li, Z., Bi, L., Li, K., Zhou, B., Chen, X., Huang, J., & Xu, K. (2014) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-014-2069-4 · Cited by 60
Lebok, P., ÖZTÜRK, M., Heilenkötter, U., Jaenicke, F., Müller, V., Paluchowski, P., Geist, S., Wilke, C., BURANDT, E., Lebeau, A., et al. (2016) · Oncology Letters · doi:10.3892/ol.2016.4206 · Cited by 60
Atrafi, F., van Eerden, R. A. G., Vlieg, M. A. M. V. H., Hoop, E. O., de Bruijn, P., Lolkema, M. P., Moelker, A. D., Rijcken, C. J. F., Hanssen, R., Sparreboom, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0008 · Cited by 60
Concurrent Paclitaxel and Radiation in the Treatment of Locally Advanced Head and Neck Cancer
Sunwoo, J. B., Herscher, L. L., Kroog, G. S., Thomas, G. R., Ondrey, F. G., Duffey, D. C., Solomon, B. I., Boss, C., Albert, P. S., McCullugh, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.800 · Cited by 59
Battista, T., Fiorillo, A., Chiarini, V., Genovese, I., Ilari, A., & Colotti, G. (2020) · Cancers · doi:10.3390/cancers12040887 · Cited by 59
Self-citationQi, J., Liu, N., Zhou, Y., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.08.042 · Cited by 58
Mad2 and BubR1 modulates tumourigenesis and paclitaxel response in MKN45 gastric cancer cells
Bargiela-Iparraguirre, J., Prado-Marchal, L., Pajuelo‐Lozano, N., Jiménez, B., Perona, R., & Sánchez‐Pérez, I. (2014) · Cell Cycle · doi:10.4161/15384101.2014.962952 · Cited by 58
Mimeault, M., Johansson, S. L., Hénichart, J., Depreux, P., & Batra, S. K. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1013 · Cited by 58
Gillet, J., Calcagno, A. M., Varma, S., Davidson, B., Elstrand, M. B., Ganapathi, R. N., Kamat, A. A., Sood, A. K., Ambudkar, S. V., Seiden, M. V., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0056 · Cited by 57
Dexter, D., Reddy, R. K., Geles, K. G., Bansal, S., Myint, M. A., Rogakto, A., Leighton, J. C., & Goldstein, L. J. (1998) · PubMed · Cited by 57
Sangrajrang, S., & Fellous, A. (2000) · Chemotherapy · doi:10.1159/000007306 · Cited by 57
Wang, J. M., Chertov, O., Proost, P., Li, J. J., Menton, P., Xu, L., Sozzani, S., Mantovani, A., Gong, W., Schirrmacher, V., et al. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980316)75:6<925::aid-ijc16>3.0.co;2-1 · Cited by 56
Sorcin, an important gene associated with multidrug-resistance in human leukemia cells
Zhou, Y., Xu, Y., Tan, Y., et al. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.08.024 · Cited by 56
Wang, Y. C., Juric, D., Francisco, B. S., Yu, R., Durán, G. E., Chen, K. G., Chen, X., & Sikic, B. I. (2005) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20300 · Cited by 56
Taxane resistance in prostate cancer is mediated by decreased drug-target engagement
Gjyrezi, A., Xie, F., Voznesensky, O. S., Khanna, P., Calagua, C., Bai, Y., Kung, J. W., Wu, J. S., Corey, E., Montgomery, B., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci132184 · Cited by 56
Gaudelot, K., Gibier, J., Pottier, N., Hémon, B., SEUNINGEN, I. V., Glowacki, F., Leroy, X., Cauffiez, C., Gnemmi, V., Aubert, S., et al. (2017) · Tumor Biology · doi:10.1177/1010428317707372 · Cited by 55
Prassanawar, S. S., & Panda, D. (2019) · Biochemical Journal · doi:10.1042/bcj20190123 · Cited by 55
Berchem, G., Bosseler, M., Mine, N., & Avalosse, B. L. (1999) · PubMed · Cited by 53
Structural basis of Sorcin-mediated calcium-dependent signal transduction
Ilari, A., Fiorillo, A., Poser, E., Lalioti, V. S., Sundell, G. N., Ivarsson, Y., Genovese, I., & Colotti, G. (2015) · Scientific Reports · doi:10.1038/srep16828 · Cited by 53
Self-citationGu, W., Zou, H., Li, L., Carcedo, I. G., Xu, Z. P., & Monteiro, M. J. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s100744 · Cited by 53
Quest for Efficacious Next-Generation Taxoid Anticancer Agents and Their Tumor-Targeted Delivery
Ojima, I., Wang, X., Jing, Y., & Wang, C. (2018) · Journal of Natural Products · doi:10.1021/acs.jnatprod.7b01012 · Cited by 53
From amplification to function: the case of the MDR1 gene
Roninson, I. B. (1992) · Mutation Research/Reviews in Genetic Toxicology · doi:10.1016/0165-1110(92)90005-t · Cited by 52
Yang, D., Ding, X., Luo, J., Shan, Y.-X., Wang, R., Lin, S.-J., Li, G., Huang, C., Zhu, J., Chen, Y., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.448142 · Cited by 52
Treatment regimens of classical and newer taxanes
Joerger, M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2893-6 · Cited by 52
Zou, W., Sarısözen, C., & Torchilin, V. P. (2016) · Journal of drug targeting · doi:10.1080/1061186x.2016.1236113 · Cited by 52
Talekar, M., Ouyang, Q., Goldberg, M. S., & Amiji, M. M. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0100 · Cited by 50
Park, S., Seong, M. A., & Lee, H. (2016) · Oncotarget · doi:10.18632/oncotarget.6945 · Cited by 50
Binding of doxorubicin to Sorcin impairs cell death and increases drug resistance in cancer cells
Genovese, I., Fiorillo, A., Ilari, A., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.342 · Cited by 50
Self-citationCurrent taxane formulations and emerging cabazitaxel delivery systems
Sun, B., Straubinger, R. M., & Lovell, J. F. (2018) · Nano Research · doi:10.1007/s12274-018-2171-0 · Cited by 50
The Potential of Combining Tubulin-Targeting Anticancer Therapeutics and Immune Therapy
Fong, A., Durkin, A., & Lee, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030586 · Cited by 50
Huang, C., Zhang, X., Jiang, L., Zhang, L., Xiang, M., & Ren, H. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.05.005 · Cited by 50
Engelberg, S., Netzer, E., Assaraf, Y. G., & Livney, Y. D. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1870-0 · Cited by 50
Self-citationTargeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy
Giovinazzi, S., Bellapu, D., Morozov, V. M., & Ishov, A. M. (2013) · Cell Cycle · doi:10.4161/cc.25591 · Cited by 49
Du, J., Li, B., Fang, Y., Liu, Y., Wang, Y., Li, J., Zhou, W., & Wang, X. (2015) · BMC Cancer · doi:10.1186/s12885-015-1553-x · Cited by 48
Lalioti, V. S., Ilari, A., O’Connell, D. J., Poser, E., Sandoval, I. V., & Colotti, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085438 · Cited by 48
Self-citationZamparelli, C., Macquaide, N., Colotti, G., et al. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.03.003 · Cited by 48
Self-citationParekh, H. K., Deng, H. B., Choudhary, K., et al. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)00850-x · Cited by 48
Blenk, S., Engelmann, J. C., Pinkert, S., Weniger, M., Schultz, J., Rosenwald, A., Müller‐Hermelink, H. K., Müller, T., & Dandekar, T. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-106 · Cited by 48
Zhang (2010) · Oncology Reports · doi:10.3892/or_00001066 · Cited by 48
Atrafi, F., Dumez, H., Mathijssen, R. H. J., van Oordt, C. W. M. D. H., Rijcken, C. J. F., Hanssen, R., Eskens, F. A. L. M., & Schöffski, P. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.020 · Cited by 48
Takano, M., Otani, Y., Tanda, M., Kawami, M., Nagai, J., & Yumoto, R. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.418 · Cited by 47
Lin, H., Hu, B., He, X., Mao, J., Wang, Y., Wang, J., Zhang, T., Zheng, J., Peng, Y., & Zhang, F. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113733 · Cited by 47
Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms
Aldonza, M. B. D., Ku, J., Hong, J., Kim, D., Yu, S. J., Lee, M.-S., Prayogo, M. C., Tan, S., Kim, D., Han, J., et al. (2020) · Science Advances · doi:10.1126/sciadv.aav7416 · Cited by 47
Mitotic Centromere-associated Kinesin (MCAK) Mediates Paclitaxel Resistance
Ganguly, A., Yang, H., Pedroza, M., Bhattacharya, R., & Cabral, F. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.296483 · Cited by 46
Shin, S., Woo, S., & Yim, H. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919846375 · Cited by 46
Zhong, P., Chen, X., Guo, R., Chen, X., Chen, Z., Cui, W., Li, Y., Wang, W. “., Zhou, Y., & Qin, L. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01148 · Cited by 46
The Quest for a Simple Bioactive Analog of Paclitaxel as a Potential Anticancer Agent
Kingston, D. G. I., & Snyder, J. P. (2014) · Accounts of Chemical Research · doi:10.1021/ar500203h · Cited by 45
Su, W.-P., Lo, Y.-C., Yan, J., Liao, I., Tsai, P.-J., Wang, H., Yeh, H.-H., Lin, C., Chen, H. H. W., Lai, W., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs253 · Cited by 45
Current and Emerging Options for Taxol Production
Li, Y., Zhang, G., & Pfeifer, B. A. (2014) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2014_292 · Cited by 44
Krishnamurthy, K., Vedam, K., Kanagasabai, R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200731109 · Cited by 44
Assaraf, Y. G., Molina, A., & SCHIMKE, R. T. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.4.290 · Cited by 44
Self-citationZhang, W., Cai, J., Chen, S., Zheng, X., Hu, S., Dong, W., Lü, J., Xing, J., & Dong, Y. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3468 · Cited by 44
He, J., Shi, X., Li, Z., Pan, X., Li, Z., Chen, Y., Yan, S.-J., & Xiao, L. (2019) · BMC Molecular and Cell Biology · doi:10.1186/s12860-019-0227-y · Cited by 44
Li, Z., Chan, K., Qi, Y., Lu, L., Ning, F., Wu, M., Wang, H., Wang, Y., Cai, S., & Du, J. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2017.356 · Cited by 43
Yuan, Y., Yao, Y. F., Hu, S. N., Gao, J., & Zhang, L.-L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129843 · Cited by 43
Aldonza, M. B. D., Hong, J., & Lee, S. K. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.131 · Cited by 43
Targa, B., Klipfel, L., Cantaloube, I., Salameh, J., Benoit, B., Poüs, C., & Baillet, A. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1318-6 · Cited by 42
Hara, T., Ushio, K., Nishiwaki, M., Kouno, J., Araki, H., Hikichi, Y., Hattori, M., Imai, Y., & Yamaoka, M. (2009) · Cell Biology International · doi:10.1042/cbi20090030 · Cited by 41
Wang, W., Shi, Y., Li, J., Cui, W., & Yang, B. (2016) · Bioscience Reports · doi:10.1042/bsr20150314 · Cited by 41
Gupta, R. S. (1985) · PubMed · Cited by 41
Expression of a Multidrug Resistance Gene in Blast Crisis of Chronic Myelogenous Leukemia
Pirker, R., Goldstein, L. J., Ludwig, H., et al. (1989) · Cancer Communications · doi:10.3727/095535489820875354 · Cited by 41
Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer
Galletti, G., Zhang, C., Gjyrezi, A., Cleveland, K., Zhang, J., Powell, S., Thakkar, P. V., Betel, D., Shah, M. A., & Giannakakou, P. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3018 · Cited by 41
Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells
Qiu, X., Wang, W., Li, B., Cheng, B., Lin, K., Bai, J., Li, H., & Yang, G. (2019) · BMC Cancer · doi:10.1186/s12885-018-5228-2 · Cited by 40
Broxterman, H. J., Sonneveld, P., Pieters, R., Lankelma, J., Eekman, C., Loonen, A. H., Schoester, M., Ossenkoppele, G. J., Löwenberg, B., Pinedo, H. M., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401331 · Cited by 39
Huang, J., Peng, W., Zheng, Y., Hu, H., Li, S., Yao, Y., Ding, Y., Zhang, J., Lyu, J., & Zeng, Q. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/2758262 · Cited by 39
Parmakhtiar, B., Burger, R. A., Kim, J.-H., & Fruehauf, J. P. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1109 · Cited by 39
Paradoxical mitotic exit induced by a small molecule inhibitor of APC/CCdc20
Richeson, K. V., Bodrug, T., Sackton, K. L., Yamaguchi, M., Paulo, J. A., Gygi, S. P., Schulman, B. A., Brown, N. G., & King, R. W. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0495-z · Cited by 39
Donehower, R. C. (1996) · Stem Cells · doi:10.1002/stem.140025 · Cited by 38
Sobue, S., Mizutani, N., Aoyama, Y., Kawamoto, Y., Suzuki, M., Nozawa, Y., Ichihara, M., & Murate, T. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.09.128 · Cited by 38
Qu, Y.-C., Cong, P., Lin, C.-J., Deng, Y., Li‐Ling, J., & Zhang, M. (2017) · Oncology Letters · doi:10.3892/ol.2017.6148 · Cited by 38
Franceschini, S., Ilari, A., Verzili, D., et al. (2007) · The FASEB Journal · doi:10.1096/fj.07-8988com · Cited by 37
Self-citationExpression of Functional Markers in Acute Nonlymphoblastic Leukemia
Han, K., Kahng, J., Kim, M., Lim, J., Kim, Y., Cho, B., Kim, H. K., Min, W. S., Kim, C. C., Lee, K. Y., et al. (2000) · Acta Haematologica · doi:10.1159/000046511 · Cited by 37
Wang, Z., Goulet, R. J., Stanton-Maxey, K. J., Sadaria, M. R., & Nakshatri, H. (2005) · PubMed · Cited by 37
Taxanes with high potency inducing tubulin assembly overcome tumoural cell resistances
Matesanz, R., Trigili, C., Rodríguez‐Salarichs, J., Zanardi, I., Pera, B., Nogales, A., Fang, W., Jiménez‐Barbero, J., Canales, Á., Barasoaı́n, I., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.05.048 · Cited by 36
Zheng, X., Andruska, N. D., Lambrecht, M. J., He, S., Parissenti, A. M., Hergenrother, P. J., Nelson, E. R., & Shapiro, D. J. (2016) · Oncotarget · doi:10.18632/oncotarget.10819 · Cited by 36
Yakisich, J. S., Azad, N., Kaushik, V., & Iyer, A. K. V. (2019) · Stem Cells International · doi:10.1155/2019/6254269 · Cited by 36
Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy
Pandya, A. D., Jäger, E., Fam, S. B., Höcherl, A., Jäger, A., Sincari, V., Nyström, B., Štěpánek, P., Skotland, T., Sandvig, K., et al. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s208938 · Cited by 36
Yu, J., Hu, F., Zhu, Q., Li, X., Ren, H., Fan, S., Qian, B., Zhai, B., & Yang, D. (2020) · Nanoscale Research Letters · doi:10.1186/s11671-019-3228-z · Cited by 36
Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line
Hata, K., Osaki, M., Dhar, D. K., Nakayama, K., Fujiwaki, R., Ito, H., Nagasue, N., & Miyazaki, K. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0693-x · Cited by 35
Liu, Y., She, M., Wu, Z., & Dai, R. (2010) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2010.518965 · Cited by 34
Kao, C., Tsai, S., Liu, T., Ho, Y., Wang, J., Ho, S., & ChangLai, S.-P. (2001) · PubMed · Cited by 34
Hansen, S., Ehlers, N. S., Zhu, S., Thomsen, M. B. H., Nielsen, R. L., Liu, D., Wang, G., Hou, Y., Zhang, X., Xu, X., et al. (2016) · BMC Genomics · doi:10.1186/s12864-016-2749-4 · Cited by 34
Chung, W.-M., Ho, Y.-P., Chang, W., Dai, Y., Chen, L., Hung, Y., & Ma, W. (2019) · Cancers · doi:10.3390/cancers11040463 · Cited by 34
Ferreira, P., Roela, R. A., López, R. V. M., & Estevez-Diz, M. D. P. (2020) · Oncotarget · doi:10.18632/oncotarget.27246 · Cited by 34
ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells
Sarkar, S., Mazumdar, A., Dash, R., Sarkar, D., Fisher, P. B., & Mandal, M. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22343 · Cited by 32
Hypoxia and Noncoding RNAs in Taxane Resistance
Pucci, P., Rescigno, P., Sumanasuriya, S., Bono, J. S. D., & Crea, F. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.05.002 · Cited by 32
Assaraf, Y. G., & Borgnia, M. J. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.tb18928.x · Cited by 30
Self-citationP-Glycoprotein Expression in Bladder Cancer
Park, J., Shinohara, N., Liebert, M., et al. (1994) · The Journal of Urology · doi:10.1016/s0022-5347(17)34868-1 · Cited by 30
Site occupancy calibration of taxane pharmacology in live cells and tissues
Pineda, J. J., Miller, M. A., Song, Y., Kuhn, H., Mikula, H., Tallapragada, N. P., Weissleder, R., & Mitchison, T. J. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1800047115 · Cited by 30
Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer
Ma, L., Yan, Y., Bai, Y., Yang, Y., Pan, Y., Gang, X., Karnes, R. J., Zhang, J., Lv, Q., Wu, Q., et al. (2019) · Theranostics · doi:10.7150/thno.34700 · Cited by 30
Recent advances in understanding the role of Cdk1 in the Spindle Assembly Checkpoint
Serpico, A. F., & Grieco, D. (2020) · F1000Research · doi:10.12688/f1000research.21185.1 · Cited by 30
Field, J., Northcote, P. T., Paterson, I., Altmann, K., Díaz, J. F., & Miller, J. H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050971 · Cited by 29
Structural definition of polyspecific compensatory ligand recognition by P-glycoprotein
Le, C. A., Harvey, D. S., & Aller, S. G. (2020) · IUCrJ · doi:10.1107/s2052252520005709 · Cited by 29
Churchill, C. D. M., Kłobukowski, M., & Tuszyński, J. A. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12595 · Cited by 28
2-(m-Azidobenzoyl)taxol binds differentially to distinct β-tubulin isotypes
Yang, C., Yap, E.-H., Xiao, H., Fiser, A., & Horwitz, S. (2016) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1613286113 · Cited by 28
Melanoma cell sensitivity to Docetaxel‐induced apoptosis is determined by class III β‐tubulin levels
Mhaidat, N. M., Thorne, R. F., de Bock, C. E., Zhang, X. D., & Hersey, P. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.12.014 · Cited by 27
Novel oral taxane therapies: recent Phase I results
Flores, J. P., & Saif, M. W. (2013) · Clinical Investigation · doi:10.4155/cli.13.18 · Cited by 26
Mostoufi, H., Yousefi, G., Tamaddon, A. M., & Firuzi, O. (2018) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2018.10.072 · Cited by 26
Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma
Szende, B., Romics, I., Minik, K., Szabó, J., Torda, I., Lovász, S., Szomor, L., Tóth, L., Bely, M., Kerënyi, T., et al. (2001) · The Prostate · doi:10.1002/pros.1122 · Cited by 25
Reversing Effect of Sorcin in the Drug Resistance of Human Nasopharyngeal Carcinoma
Liu, X., Chen, L., Feng, B., et al. (2013) · The Anatomical Record · doi:10.1002/ar.22832 · Cited by 24
Antileukemic effect of paclitaxel in combination with metformin in HL-60 cell line
Aşık, A., Kayabaşı, Ç., Yelken, B. Ö., Süslüer, S. Y., Şiğva, Z. Ö. D., Okcanoğlu, T. B., Saydam, G., Avcı, Ç. B., & Gündüz, C. (2018) · Gene · doi:10.1016/j.gene.2018.01.017 · Cited by 24
Zou, Z., Zhang, J., Zhang, H., Liu, H., Li, Z., Cheng, D., Chen, J., Liu, L., Ni, M., Zhang, Y. X., et al. (2014) · Journal of drug targeting · doi:10.3109/1061186x.2014.936870 · Cited by 23
Khatami, M. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0193-6 · Cited by 23
A Synthetic Manassantin A Derivative Inhibits Hypoxia-Inducible Factor 1 and Tumor Growth
Lang, L., Liu, X., Li, Y., Zhou, Q., Xie, P., Yan, C., & Chen, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099584 · Cited by 22
Developing Body-Components-Based Theranostic Nanoparticles for Targeting Ovarian Cancer
Edelman, R., Assaraf, Y. G., Slavkin, A., Dolev, T., Shahar, T., & Livney, Y. D. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11050216 · Cited by 22
Self-citationHüsemann, L., Reese, A., Radine, C., Piekorz, R. P., Budach, W., Sohn, D., & Jänicke, R. U. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1716144 · Cited by 22
EFFECT OF P-GLYCOPROTEIN EXPRESSION ON OUTCOME IN THE EWING FAMILY OF TUMORS
Perri, T., Fogel, M., Mor, S., Horev, G., Meller, I., Loven, D., Issakov, J., Kollender, Y., Smirnov, A., Zaizov, R., et al. (2001) · Pediatric Hematology and Oncology · doi:10.1080/088800101300312591 · Cited by 21
The relationship between p38MAPK and apoptosis during paclitaxel resistance of ovarian cancer cells
Lu, M., Xiao, L., Li, Z., & Hu, J. (2007) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-007-0628-6 · Cited by 21
Hao, D., Xiao, P., & Chen, S. (2010) · Science China Life Sciences · doi:10.1007/s11427-010-4062-9 · Cited by 21
Yuan, S., Zhu, L., Zheng, W., Chen, H., Wu, L. J., Zhang, W., Sun, H., & Chen, W. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.1.361 · Cited by 21
Torigoe, K., Sato, S., Kusaba, H., et al. (1995) · Genome Research · doi:10.1101/gr.5.3.233 · Cited by 21
Loo, W. T. Y., Fong, J. H. M., Cheung, M., & Chow, L. W. C. (2005) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(05)80069-1 · Cited by 20
Advani, R. H., Lum, B. L., Fisher, G. A., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi396 · Cited by 20
Kitada, K., & Yamasaki, T. (2007) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2007.06.014 · Cited by 19
Kudoh, A., Oishi, T., Itamochi, H., Sato, S., Naniwa, J., Sato, S., Shimada, M., Kigawa, J., & Harada, T. (2014) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000091 · Cited by 19
Asghari, F., Haghnavaz, N., Shanehbandi, D., Khaze, V., Baradaran, B., & Kazemi, T. (2018) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/70745 · Cited by 19
Shanker, N., Kingston, D. G. I., Ganesh, T., Yang, C., Alcaraz, A. A., Geballe, M. T., Banerjee, A., McGee, D. W., Snyder, J. P., & Bane, S. (2007) · Biochemistry · doi:10.1021/bi700753y · Cited by 18
βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel
Smiyun, G., Azarenko, O., Miller, H., Rifkind, A., LaPointe, N. E., Wilson, L., & Jordan, M. A. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3345-2 · Cited by 18
The effect of some antineoplastic agents on glutathione S-transferase from human erythrocytes
Erat, M., & Şakiroğlu, H. (2012) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2012.677837 · Cited by 16
Extracellular Vesicle-Mediated Reversal of Paclitaxel Resistance in Prostate Cancer
Wang, J. Q., DeChalus, A., Chatterjee, D. N., Keller, E. T., Mizokami, A., Camussi, G., Mendelsohn, A. R., Renzulli, J., Quesenberry, P. J., & Chatterjee, D. (2015) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v20.i5-6.120 · Cited by 15
Analysis of resistance-associated gene expression in docetaxel-resistant prostate cancer cells
Lee, S.-C., Kim, K. T., Ho, J., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.6541 · Cited by 12
Mu, X. L., Chen, M., Xiao, B., Yang, B., Singh, S., & Zhang, B. (2019) · DNA and Cell Biology · doi:10.1089/dna.2019.4699 · Cited by 12
Molecular bases of Sorcin-dependent resistance to chemotherapeutic agents
Genovese, I., Ilari, A., Battista, T., Chiarini, V., Fazi, F., Fiorillo, A., & Colotti, G. (2018) · Cancer Drug Resistance · doi:10.20517/cdr.2018.10 · Cited by 9
Self-citationCai, X., Hu, B., Liu, S., Liu, M., Huang, Y., Lei, P., Zhang, Z., He, Z., Linquan, Z., & Huang, R. (2020) · Oncology Letters · doi:10.3892/ol.2020.11972 · Cited by 9
TaxKB: a knowledge base for new taxane-related drug discovery
Murugan, K., Shanmugasamy, S., Al-Sohaibani, S., Vignesh, N., Palanikannan, K., Antonydhason, V., & Kumar, G. R. (2015) · BioData Mining · doi:10.1186/s13040-015-0053-5 · Cited by 6
Cited by
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071796 · Cited by 511
Therapeutic strategies to overcome taxane resistance in cancer
Das, T., Anand, U., Pandey, S. K., Ashby, C. R., Assaraf, Y. G., Chen, Z.-S., & Dey, A. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100754 · Cited by 253
Self-citationLi, Y., Xu, C., Wang, B., Xu, F., Ma, F., Qu, Y., Jiang, D., Li, K., Feng, J., Tian, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33282-0 · Cited by 80
Du, R., You, Q., Liu, J., Wang, C., Zhu, L., & Yang, Y. (2023) · Nano Research · doi:10.1007/s12274-023-6105-0 · Cited by 19
Metadata
- Authors
- Mosca, L., Ilari, A., Fazi, F., Assaraf, Y. G., & Colotti, G.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 54
- Pages
- 100742
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W3120588454
- Cited by
- 385
- References
- 539
- FWCI
- 18.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.